{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:53:56Z","timestamp":1761544436615,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"am","delay-in-days":364,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["HHSF223201810183C"],"award-info":[{"award-number":["HHSF223201810183C"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001998"],"award-info":[{"award-number":["UL1TR001998"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.japh.2022.07.017","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T04:46:10Z","timestamp":1659588370000},"page":"1836-1842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Kentucky pharmacists\u2019 experiences in dispensing abuse-deterrent opioid analgesics"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6153-831X","authenticated-orcid":false,"given":"Douglas R.","family":"Oyler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4541-6574","authenticated-orcid":false,"given":"Svetla","family":"Slavova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3727-8116","authenticated-orcid":false,"given":"John R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabarun","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia R.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.japh.2022.07.017_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2217\/pmt-2019-0052","article-title":"Abuse-deterrent opioid analgesics: a guide for clinicians","volume":"10","author":"Carinci","year":"2020","journal-title":"Pain Manag"},{"issue":"6","key":"10.1016\/j.japh.2022.07.017_bib3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.5055\/jom.2017.0412","article-title":"Evaluating the abuse potential of opioids and abuse-deterrent opioid formulations: a review of clinical study methodology","volume":"13","author":"Setnik","year":"2017","journal-title":"J\u00a0Opioid Manag"},{"key":"10.1016\/j.japh.2022.07.017_bib4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/JMDH.S166915","article-title":"An overview of abuse-deterrent opioids and recommendations for practical patient care","volume":"11","author":"Adler","year":"2018","journal-title":"J\u00a0Multidiscip Healthc"},{"issue":"12","key":"10.1016\/j.japh.2022.07.017_bib5","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1634\/theoncologist.2019-0340","article-title":"Dancing with deterrents: understanding the role of abuse-deterrent opioid formulations and naloxone in managing cancer pain","volume":"24","author":"Mitchell","year":"2019","journal-title":"Oncologist"},{"issue":"50","key":"10.1016\/j.japh.2022.07.017_bib9","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.15585\/mmwr.mm7050e3","article-title":"Trends in and characteristics of drug overdose deaths involving illicitly manufactured fentanyls - United States, 2019-2020","volume":"70","author":"O'Donnell","year":"2021","journal-title":"Morb Mortal Wkly Rep"},{"author":"Steel","key":"10.1016\/j.japh.2022.07.017_bib11"},{"issue":"3","key":"10.1016\/j.japh.2022.07.017_bib13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/cpt.390","article-title":"The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting","volume":"100","author":"Coplan","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.japh.2022.07.017_bib14","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1001\/jamapsychiatry.2014.3043","article-title":"Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from OxyContin","volume":"72","author":"Cicero","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.japh.2022.07.017_bib15","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/jamainternmed.2015.0914","article-title":"Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene","volume":"175","author":"Larochelle","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.japh.2022.07.017_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1257\/pol.20170082","article-title":"Supply-side drug policy in the presence of substitutes: evidence from the introduction of abuse-deterrent opioids","volume":"10","author":"Alpert","year":"2018","journal-title":"Am Econ J Econ Policy"},{"issue":"10","key":"10.1016\/j.japh.2022.07.017_bib18","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2105\/AJPH.2018.304590","article-title":"Modeling health benefits and harms of public policy responses to the US opioid epidemic","volume":"108","author":"Pitt","year":"2018","journal-title":"Am J Public Health"},{"year":"2020","series-title":"FDA briefing document: Joint meeting of the Drug Safety and RISK MANAGEMent Advisory Committee and Anesthetic and Analgesic Drug Products Advisory Committee","key":"10.1016\/j.japh.2022.07.017_bib19"},{"key":"10.1016\/j.japh.2022.07.017_bib20","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/pme.12295","article-title":"Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation","volume":"15","author":"Cassidy","year":"2014","journal-title":"Pain Med"},{"issue":"1","key":"10.1016\/j.japh.2022.07.017_bib21","first-page":"21","article-title":"Association between formulary coverage and use of abuse-deterrent prescription opioids, risk for abuse or overdose, and associated healthcare resource utilization","volume":"13","author":"Petrilla","year":"2020","journal-title":"Am Health Drug Benefits"},{"issue":"5","key":"10.1016\/j.japh.2022.07.017_bib22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/pds.4287","article-title":"Important statistical considerations in the evaluation of post-market studies to assess whether opioids with abuse-deterrent properties result in reduced abuse in the community","volume":"27","author":"By","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.japh.2022.07.017_bib23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/FTD.0000000000000844","article-title":"Abuse-deterrent opioid formulations and the opioid crisis: a pharmacist\u2019s perspective","volume":"43","author":"Gadd","year":"2021","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.japh.2022.07.017_bib24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J\u00a0Biomed Inform"},{"author":"Freeman","key":"10.1016\/j.japh.2022.07.017_bib25"},{"issue":"1","key":"10.1016\/j.japh.2022.07.017_bib26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40122-021-00343-z","article-title":"Abuse-deterrent opioids: a survey of physician beliefs, behaviors, and psychology","volume":"11","author":"Dasgupta","year":"2022","journal-title":"Pain Ther"},{"issue":"1","key":"10.1016\/j.japh.2022.07.017_bib27","first-page":"23","article-title":"Variation in abuse-deterrent formulation opioid prescribing in California, Florida, and Kentucky in 2018","volume":"37","author":"Brown","year":"2021","journal-title":"J\u00a0Rural Health"},{"key":"10.1016\/j.japh.2022.07.017_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109232","article-title":"The effect of state policies on rates of high-risk prescribing of an initial opioid analgesic","volume":"231","author":"Stein","year":"2022","journal-title":"Drug Alcohol Depend"},{"year":"2018","series-title":"Provisional Drug Overdose Death Counts","author":"Ahmad","key":"10.1016\/j.japh.2022.07.017_bib30"},{"author":"American College of Rheumatology","key":"10.1016\/j.japh.2022.07.017_bib32"},{"issue":"5","key":"10.1016\/j.japh.2022.07.017_bib33","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/pm\/pnx232","article-title":"ADF: abuse-deterrent formulation or another disillusioned formulation?","volume":"19","author":"Brooks","year":"2018","journal-title":"Pain Med"},{"issue":"3","key":"10.1016\/j.japh.2022.07.017_bib34","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/add.14517","article-title":"What are our aims, and why?","volume":"114","author":"Jauncey","year":"2019","journal-title":"Addiction"},{"issue":"4S","key":"10.1016\/j.japh.2022.07.017_bib35","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/j.japh.2021.01.016","article-title":"National survey identifying community pharmacist preceptors' experience, knowledge, attitudes, and behaviors influencing intent to recommend cannabidiol products","volume":"61","author":"Nichols","year":"2021","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"2","key":"10.1016\/j.japh.2022.07.017_bib36","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.japh.2019.11.004","article-title":"Pharmacist attitudes toward pharmacy-based naloxone: a cross-sectional survey study","volume":"60","author":"Burstein","year":"2020","journal-title":"J\u00a0Am Pharm Assoc"},{"key":"10.1016\/j.japh.2022.07.017_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109518","article-title":"Availability of buprenorphine\/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states","volume":"237","author":"Hill","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.japh.2022.07.017_bib38","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/ACM.0000000000002088","article-title":"Why open-ended survey questions are unlikely to support rigorous qualitative insights","volume":"93","author":"LaDonna","year":"2018","journal-title":"Acad Med"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319122002709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319122002709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:50:34Z","timestamp":1761544234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319122002709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1544319122002709"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2022.07.017","relation":{},"ISSN":["1544-3191"],"issn-type":[{"type":"print","value":"1544-3191"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kentucky pharmacists\u2019 experiences in dispensing abuse-deterrent opioid analgesics","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2022.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}